Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis on Marvel stock, CostCO stock, and CrowdStrike stock.

3 extracted signals · 3 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor13 Sept 2025, 21:26 UTC
Video preview for Friends! In this video, I'm going to do an analysis on Marvel stock, CostCO stock, and CrowdStrike stock.
Signals
3
Eligible signals in this source
Open
0
Still being tracked
Resolved
3
Evaluable outcomes
Successful
1
Canonical correct result
Failed
2
Canonical failed result
Resolved success
33.33%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on three stocks: CRM, FTNT, and CMG. CRM's revenue growth has peaked, and its P/FCF multiple has decreased, suggesting a potential bearish outlook. FTNT, despite being a cybersecurity play, shows slowing revenue growth and has faced analyst scrutiny, leading to a potential valuation reset. CMG, while having a strong brand, is experiencing a significant slowdown in revenue growth and a decline in its stock price, making it a high-risk, high-reward opportunity. The overall market sentiment suggests caution due to decelerating growth and potentially overvalued multiples in some sectors.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    3 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.